Information Provided By: 
Fly News Breaks for December 7, 2015
BLUE
Dec 7, 2015 | 08:05 EDT
Roth Capital believes that data presented over the weekend indicates that the therapeutic benefit seen in B-thalassemia patients who receive bluebird's treatment "may not be durable." The firm also notes that the initial data from two sickle cell patients who received bluebird's treatment has not been as strong as that of an earlier patient. Target to $62 from $121.
News For BLUE From the Last 2 Days
There are no results for your query BLUE
